Dear Pharmaceutical Professional,

The multiple myeloma market will be impacted by data presented during the virtual American Society of Hematology (ASH) meeting. With this year’s new virtual format, do you have a strategy for understanding the commercial impact of breaking data in multiple myeloma?

As seasoned experts in bringing congress data to hematologists/oncologists in their practice, our team will be working with 30 hem/oncs during the meeting to better understand the commercial implications of data presented for:

    idecabtagene vicleucel (ide-cel, bb2121)
    P-BCMA-101 CAR-T cells
    ciltacabtagene autoleucel
    teclistamab
    talquetamab
    REGN5458 (a BCMA x CD3 Bispecific Monoclonal Antibody)
    iberdomide (IBER; CC-220) + dexamethasone + daratumumab or bortezomib
    belantamab mafodotin (belamaf)
    belmaf + bortezomib + dexamethasone
    daratumumab + pomalidomide + dexamethasone vs. pomalidomide + dexamethasone
    selinexor + bortezomib + dexamethason vs. bortezomib + dexamethasone
    pomalidomide + dexamethasone + daratumumab after lenalidomide
    carfilzomib + dexamethasone + daratumumab vs. carfilzomib + dexamethasone

Order your 60-slide report so you can make better decisions today and prepare for tomorrow.

Sincerely,

The Breaking Data Team

Multiple Myeloma ASH 2020

American Society of Hematology

Virtual Meeting
December 5 to December 8

Share:

Stay Connected with Hem/Oncs at ASH 2020

Learn More